Sign In
Buy RLFTF
$0.246
+0.0027 (+1.12%)
At Close: Jul 31, 2026
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
01:20am, Tuesday, 05'th Dec 2023
GENEVA, SWITZERLAND / ACCESSWIRE / December 5, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering i
Relief Therapeutics Announces CEO Transition
03:00am, Wednesday, 22'nd Nov 2023
GENEVA, SWITZERLAND / ACCESSWIRE / November 22, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering
GENEVA, SWITZERLAND / ACCESSWIRE / October 10, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering i
Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update
02:15am, Friday, 15'th Sep 2023
GENEVA, SWITZERLAND / ACCESSWIRE / September 15, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering
Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
03:15am, Friday, 01'st Sep 2023
GENEVA, SWITZERLAND / ACCESSWIRE / September 1, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief Therapeutics), a biopharmaceutical company committed to delivering inn
Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA(TM) (ACER-001) with Acer Therapeutics
05:40pm, Wednesday, 30'th Aug 2023
Acer Therapeutics buys Relief Therapeutics' stake in OLPRUVA™ worldwide, excluding geographical Europe, providing an upfront payment of $10 million in cash to Relief Therapeutics with the potential
Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE(R) in the U.S. with Pentec Health
02:00am, Wednesday, 19'th Jul 2023
Recent Pentech Health acquisition of ZOIA Pharma broadens distribution and access for patients to PKU GOLIKE® GENEVA, SWITZERLAND / ACCESSWIRE / July 19, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RL
The results of the preclinical study demonstrate improved muscle anabolism and function with a prolonged-release amino acid supplement using Physiomimic Technology™ GENEVA, SWITZERLAND / ACCESSWIRE
FDA Rejects Acer Therapeutics - Relief Therapeutics' Urea Cycle Disorder Candidate
01:21pm, Tuesday, 21'st Jun 2022
The FDA issued a Complete Response Letter regarding the marketing application for Acer Therapeutics Inc (NASDAQ: ACER) and its collaboration partner, Relief Therapeutics Holding SA's (OTC: RLFTF
Relief Therapeutics to Participate in Virtual Investor Conferences in January
01:20am, Wednesday, 05'th Jan 2022
GENEVA, SWITZERLAND / ACCESSWIRE / January 5, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic reli
Relief Therapeutics to Webcast Live at Life Sciences Investor Forum on December 16th
08:35am, Friday, 10'th Dec 2021
GENEVA, Dec. 10, 2021 /PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from seriou
Relief Therapeutics' Subsidiary Posts Early Data For Nasal Spray COVID-19 Treatment
09:06am, Wednesday, 27'th Oct 2021
Relief Therapeutics Holding SA's (OTC: RLFTF) wholly-owned subsidiary, APR Applied Pharma Research SA, has reported interim results from its clinical trial of nasal spray Sentinox in COVID-19. Reli
GENEVA, SWITZERLAND / ACCESSWIRE / October 15, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief fro
Lawsuit alleges multiple breaches of Collaboration Agreement GENEVA, SWITZERLAND / ACCESSWIRE / October 7, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) ("Relief"), today announced that
As an Active Cleanser, Nexodyn(R) AOS Shows Superior Wound Healing Performance Compared to Standard of Care GENEVA, SWITZERLAND / ACCESSWIRE / September 30, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:
